Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, T-Cell 3Recurrence 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Leukemia, Lymphoid 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × duvelisib × Clear all
NCT03372057 2025-03-07

PRIMO

SecuraBio

Phase 2 Completed
156 enrolled 21 charts
Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡